1118567-13-7

Basic information

• Product Name: 2-(2,2-difluoroethoxy)ethyl-4-methylbenzenesulfonate
• Synonyms: 2-(2,2-difluoroethoxy)ethyl-4-methylbenzenesulfonate
• CAS NO: 1118567-13-7
• Molecular Weight: 280.293
• Mol File: 1118567-13-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(2,2-difluoroethoxy)ethyl-4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2-difluoroethoxy)ethyl-4-methylbenzenesulfonate(1118567-13-7)
• EPA Substance Registry System: 2-(2,2-difluoroethoxy)ethyl-4-methylbenzenesulfonate(1118567-13-7)

Safety Data

• Hazardous Substances Data: 1118567-13-7(Hazardous Substances Data)

Upstream product

• 853005-07-9 2-(2,2-difluoroethoxy)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1204221-55-5 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(2,2-difluoroethoxy)ethoxy)phenyl)methyl-d2)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1204221-35-1 4-bromo-1-chloro-2-(4-(2-(2,2-difluoroethoxy)ethoxy)benzyl)benzene 
• 1118567-14-8 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(2,2-difluoroethoxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Glucopyranosyl derivative and application thereof in medicines

The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.

BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.